AstraZeneca PLC — Director's Dealing 2020

Feb 7, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aevi Genomic Medicine, Inc. (GNMX)
CIK: 0001138776
Period of Report: 2019-12-19

Reporting Person: ASTRAZENECA PLC (10% Owner)
Reporting Person: MedImmune Ltd (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-19	Common Stock	P	12946900	—	Acquired	12946900	Indirect

Footnotes

F1: All of these securities were issued to MedImmune Limited in satisfaction of the Issuer's obligations to MedImmune Limited pursuant to the Option and License Agreement, dated August 6, 2019, between the Issuer and MedImmune Limited.

F2: All of these securities are owned by MedImmune Limited, which is a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC may be deemed to beneficially own the shares held by MedImmune Limited, but disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any.